Primary aldosteronism: emerging trends

Area of Science:

• Endocrinology
• Cardiology
• Hypertension Research

Background:

• Primary aldosteronism (PA) is the leading cause of endocrine hypertension (HTN).
• Recent studies indicate PA may be under-diagnosed, with expanded screening criteria due to non-classical presentations (e.g., absence of hypokalemia) and familial forms.
• The aldosterone:renin ratio (ARR) is the primary screening tool for PA.

Purpose of the Study:

• To review the diagnostic approach to primary aldosteronism.
• To highlight the importance of expanded screening and diagnostic methods.
• To emphasize the benefits of targeted therapy for PA.

Main Methods:

• Discussion of the aldosterone:renin ratio (ARR) as a screening test.
• Explanation of adrenal venous sampling (AVS) for lateralization.
• Review of current understanding of PA prevalence and diagnosis.

Main Results:

• The ARR is a reliable screening test for PA, interpretable on most antihypertensive medications.
• Adrenal venous sampling (AVS) is essential for differentiating unilateral adenomas from bilateral disease when surgical intervention is considered.
• Targeted medical or surgical therapies significantly improve patient outcomes in PA.

Conclusions:

• Primary aldosteronism is a prevalent and often overlooked cause of hypertension.
• Early and accurate diagnosis through ARR and AVS is critical.
• Effective management strategies, including surgery or medication, lead to improved patient health outcomes.